This content is from: Premium

Nuvation Bio Flounders After EcoR1 SPAC Merger

In just five days the shares of the biopharma company that merged with Oleg Nodelman’s blank check company fell by more than one-third.

A merger between a SPAC and a fledgling biopharma company is a speculative match.When both companies go public, neither of them have assets or revenues, just the capital they raised from investors.The special purpose acquisition company has promised to do a deal with a viable business and company with promising

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content